While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-... Jan 21
... Jan 16
Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild ... Jan 12
... Dec 22
ACTIV-3 is an NIH-led public-private partnership designed to accelerate the development of the most promising treatments and vaccine candidates for COVID-19.... Dec 18
Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalizations more than 21 days after first injection... Dec 09
... Dec 02
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in ... Nov 23
... Nov 09
... Oct 29
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world... Oct 24
Sanofi and Translate Bio today announced the preclinical results of an mRNA-based vaccine candidate against SARS-CoV-2... Oct 15
-Advertisements-
Thursday, May 02, 2024
.jpeg)
